Cargando…

Myosin Modulators: The New Era of Medical Therapy for Systolic Heart Failure and Hypertrophic Cardiomyopathy

A new uprising pharmacological treatment for systolic heart failure and hypertrophic cardiomyopathy demonstrates very promising results the last years. Myosin modulators have already been tested in numerous studies. Myosin inhibitor (mavacamten) and myosin stimulator, (omecamtiv mecarbil) exhibit th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lekaditi, Dimitra, Sakellaropoulos, Stefanos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139755/ https://www.ncbi.nlm.nih.gov/pubmed/34046107 http://dx.doi.org/10.14740/cr1243

Ejemplares similares

Getting inside the engine - myosin modulation in hypertrophic cardiomyopathy and systolic heart failure
por: Daniels, Matthew J, et al.
Publicado: (2021)

Causes, Diagnosis, Risk Stratification and Treatment of Bicuspid Aortic Valve Disease: An Updated Review
por: Sakellaropoulos, Stefanos, et al.
Publicado: (2020)

Amphetamine Use Revealing Hypertrophic Cardiomyopathy in a Young Patient
por: Misimi, Vulnet, et al.
Publicado: (2022)

Hypertrophic Cardiomyopathy: A Cardiovascular Challenge Becoming a Contemporary Treatable Disease
por: Sakellaropoulos, Stefanos G., et al.
Publicado: (2023)

The systolic paradox in hypertrophic cardiomyopathy
por: Haland, Trine F, et al.
Publicado: (2017)

Prospects for remodeling the hypertrophic heart with myosin modulators
por: Sewanan, Lorenzo R., et al.
Publicado: (2022)

Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure
por: Day, Sharlene M., et al.
Publicado: (2022)

Moderating the Myosin Motor to Treat Hypertrophic Cardiomyopathy
por: Papp, Zoltán
Publicado: (2022)

Systolic Compression of Intramural Coronary Arteries in Hypertrophic Cardiomyopathy
por: Sayin, Muhammet Rasit, et al.
Publicado: (2012)

Regression of Systolic Anterior Motion in Progressive Hypertrophic Cardiomyopathy
por: Koren, Ofir, et al.
Publicado: (2021)

Genetics and genomics of dilated cardiomyopathy and systolic heart failure
por: Tayal, Upasana, et al.
Publicado: (2017)

Myosins and MyomiR Network in Patients with Obstructive Hypertrophic Cardiomyopathy
por: Foglieni, Chiara, et al.
Publicado: (2022)

Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy
por: Melacini, Paola, et al.
Publicado: (2010)

Diabetes outcomes in heart failure patients with hypertrophic cardiomyopathy
por: Mekhaimar, Menatalla, et al.
Publicado: (2022)

Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light
por: Trivedi, Darshan V., et al.
Publicado: (2017)

Image-Based Computational Hemodynamics Analysis of Systolic Obstruction in Hypertrophic Cardiomyopathy
por: Fumagalli, Ivan, et al.
Publicado: (2022)

The molecular phenotype of human cardiac myosin associated with hypertrophic obstructive cardiomyopathy
por: Jacques, Adam M., et al.
Publicado: (2008)

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

Mitral Annular Plane Systolic Excursion and Tricuspid Annular Plane Systolic Excursion in Cats with Hypertrophic Cardiomyopathy
por: Spalla, I., et al.
Publicado: (2017)

Systolic third sound associated with systolic anterior motion of the mitral valve in cats with obstructive hypertrophic cardiomyopathy
por: Saponaro, Vittorio, et al.
Publicado: (2023)

Machine Learning for Predicting Heart Failure Progression in Hypertrophic Cardiomyopathy
por: Fahmy, Ahmed S., et al.
Publicado: (2021)

Myocardial Structural Alteration and Systolic Dysfunction in Preclinical Hypertrophic Cardiomyopathy Mutation Carriers
por: Yiu, Kai Hang, et al.
Publicado: (2012)

Echocardiographic profiles in hypertrophic cardiomyopathy: imaging beyond the septum and systolic anterior motion
por: Pandian, Natesa G, et al.
Publicado: (2015)

Biomarker changes with systolic anterior motion of the mitral valve in cats with hypertrophic cardiomyopathy
por: Seo, Joonbum, et al.
Publicado: (2020)

Implantation of ventricular assist devices in hypertrophic cardiomyopathy with left ventricular systolic dysfunction
por: Yagi, Nobuichiro, et al.
Publicado: (2021)

Systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: a narrative review
por: Guigui, Sarah A., et al.
Publicado: (2022)

Detection of congestive heart failure by Doppler echocardiography in cats with hypertrophic cardiomyopathy
por: Rohrbaugh, Michelle N., et al.
Publicado: (2020)

Hypertrophic cardiomyopathy with heart failure and ST‐segment elevation of the lateral wall
por: Bai, Lin, et al.
Publicado: (2022)

Dilated Cardiomyopathy and Systolic Heart Failure in a Female Patient With Danon Disease
por: Stack-Pyle, Taylor J, et al.
Publicado: (2022)

Heart Transplantation in Adriamycin-Associated Cardiomyopathy in the Contemporary Era of Advanced Heart Failure Therapies
por: Ramu, Bhavadharini, et al.
Publicado: (2021)

The Hypertrophic Cardiomyopathy Myosin Mutation R453C Alters ATP Binding and Hydrolysis of Human Cardiac β-Myosin
por: Bloemink, Marieke, et al.
Publicado: (2014)

Differences of left ventricular systolic deformation in hypertensive patients with and without apical hypertrophic cardiomyopathy
por: Kao, Yu-Cheng, et al.
Publicado: (2013)

Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry
por: Marstrand, Peter, et al.
Publicado: (2020)

Unequal allelic expression of wild-type and mutated β-myosin in familial hypertrophic cardiomyopathy
por: Tripathi, Snigdha, et al.
Publicado: (2011)

Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy
por: Kawana, Masataka, et al.
Publicado: (2017)

Heart transplantation in patients with hypertrophic cardiomyopathy
por: Torres, Marta Farrero, et al.
Publicado: (2018)

Preserving mitochondria to treat hypertrophic cardiomyopathy: From rare mitochondrial DNA mutation to heart failure therapy?
por: Diwan, Abhinav
Publicado: (2023)

Mutations in myosin S2 alter cardiac myosin-binding protein-C interaction in hypertrophic cardiomyopathy in a phosphorylation-dependent manner
por: Singh, Rohit R., et al.
Publicado: (2021)

Bortezomib Plus Melphalan-Induced Cardiomyopathy Presenting as Sinus Tachycardia and Systolic Heart Failure
por: Sampat, Parth J, et al.
Publicado: (2020)

Cardiac resynchronization therapy for patients with chronic systolic heart failure secondary to Chagas cardiomyopathy in the 21(st) century
por: Bestetti, Reinaldo B.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5i45q7oj42m10bl17p263k1k16